- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06772623
Een onderzoek om de bijwerkingen, werkzaamheid en optimale dosis van intraveneus (IV) Telisotuzumab Adizutecan in combinatie met IV Budigalimab te evalueren bij volwassen deelnemers met gevorderd of gemetastaseerd niet-plaveiselcel-NSCLC zonder voorafgaande behandeling voor gevorderde ziekte en zonder bruikbare genomische veranderingen
Een open-label multi-cohort fase 1b/2-onderzoek om de veiligheid, werkzaamheid en optimale dosis telisotuzumab Adizutecan in combinatie met Budigalimab te evalueren bij gevorderd of gemetastaseerd niet-plaveiselcel-NSCLC zonder voorafgaande behandeling voor gevorderde ziekte en zonder bruikbare genomische veranderingen
Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC.
Telisotuzumab Adizutecan (ABBV-400) and budigalimab are investigational drugs being developed for the treatment of NSCLC. This study will be divided into two stages, with the first stage treating participants with several doses of telisotuzumab adizutecan in combination with budigalimab within the dose escalation regimen until the dose reached is tolerable and expected to be efficacious. In Stage 2 there will be 3 treatment groups. Two groups will receive pembrolizumab with different optimized doses of telisotuzumab adizutecan (to allow for the best dose to be studied in the future). One group will receive the standard of care (SOC) - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. Approximately 252 adult participants with NSCLC will be enrolled in the study in 132 sites worldwide.
In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of Telisotuzumab Adizutecan in combination with budigalimab until the dose of Telisotuzumab Adizutecan reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive IV optimized doses of Telisotuzumab Adizutecan in combination with IV pembrolizumab, or IV SOC - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. The study will run for a duration of approximately 33 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studiecontact
- Naam: ABBVIE CALL CENTER
- Telefoonnummer: 844-663-3742
- E-mail: abbvieclinicaltrials@abbvie.com
Studie Locaties
-
-
-
Buenos Aires, Argentinië, 1426
- Werving
- Centro Oncologico Korben /ID# 281460
-
Buenos Aires, Argentinië, 1426
- Werving
- Fundacion Respirar /ID# 281039
-
-
Buenos Aires
-
Mar del Plata, Buenos Aires, Argentinië, 7600
- Werving
- Clinca Colon /ID# 281465
-
-
Buenos Aires F.D.
-
Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentinië, 1426
- Werving
- Instituto Alexander Fleming /ID# 282704
-
-
-
-
New South Wales
-
Blacktown, New South Wales, Australië, 2148
- Werving
- Blacktown Hospital /ID# 281588
-
-
Queensland
-
Townsville, Queensland, Australië, 4814
- Werving
- Townsville University Hospital /ID# 281498
-
-
South Australia
-
Elizabeth Vale, South Australia, Australië, 5112
- Werving
- Lyell Mcewin Hospital /ID# 281860
-
-
Victoria
-
Frankston, Victoria, Australië, 3199
- Werving
- Peninsula University Hospital /ID# 281824
-
-
-
-
-
Liège, België, 4000
- Werving
- Groupe Sante CHC - Clinique du MontLegia /ID# 271760
-
-
Limburg
-
Hasselt, Limburg, België, 3500
- Werving
- Jessa Ziekenhuis - Campus Virga Jesse /ID# 268573
-
-
Oost-Vlaanderen
-
Sint-Niklaas, Oost-Vlaanderen, België, 9100
- Werving
- Vitaz /Id# 280187
-
-
West-Vlaanderen
-
Roeselare, West-Vlaanderen, België, 8800
- Werving
- AZ-Delta. /ID# 272433
-
-
-
-
Region Metropolitana Santiago
-
Santiago, Region Metropolitana Santiago, Chili, 8330032
- Werving
- Pontificia Universidad Catolica De Chile /ID# 281594
-
Vitacura, Region Metropolitana Santiago, Chili, 7650027
- Werving
- Oncored /Id# 281108
-
-
Santiago Metropolitan
-
Santiago, Santiago Metropolitan, Chili, 6900941
- Werving
- Fundacion Arturo Lopez Perez /ID# 281211
-
Santiago, Santiago Metropolitan, Chili, 7500713
- Werving
- Orlandi Oncologia /ID# 281132
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100021
- Werving
- Cancer Hospital - Chinese Academy of Medical Sciences /ID# 269715
-
-
Fujian
-
Fuzhou, Fujian, China, 350014
- Werving
- Fujian Province Cancer Hospital /ID# 269150
-
-
Guangxi
-
Liuzhou, Guangxi, China, 545006
- Werving
- Liuzhou People's hospital /ID# 269667
-
-
Henan
-
Zhengzhou, Henan, China, 450008
- Werving
- Henan Cancer Hospital /ID# 269668
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Werving
- Union Hospital - Tongji Medical College /ID# 272286
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Werving
- Hunan Province Cancer Hospital /ID# 269679
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Werving
- Nanjing Drum Tower Hospital /ID# 269762
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330209
- Werving
- The First Affiliated Hospital of Nanchang University - Xianghu Campus /ID# 269190
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710061
- Werving
- The First Affiliated Hospital of Xi'an Jiaotong University /ID# 271904
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200030
- Werving
- Shanghai Chest Hospital /ID# 269155
-
Shanghai, Shanghai Municipality, China, 200433
- Werving
- Shanghai Pulmonary Hospital /ID# 276397
-
-
Shanxi
-
Taiyuan, Shanxi, China, 030001
- Werving
- First Affiliated Hospital of Shanxi Medical University /ID# 276482
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Werving
- West China Hospital of Sichuan University /ID# 270244
-
Chengdu, Sichuan, China, 610041
- Werving
- Sichuan Province Cancer Hospital /ID# 269712
-
-
Yunnan
-
Kunming, Yunnan, China, 650106
- Werving
- Yunnan Province Cancer Hospital /ID# 272331
-
-
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Duitsland, 79106
- Werving
- Universitaetsklinikum Freiburg /ID# 268473
-
Heilbronn, Baden-Wurttemberg, Duitsland, 74078
- Werving
- Slk-Kliniken Heilbronn /ID# 269621
-
-
Bavaria
-
Augsburg, Bavaria, Duitsland, 86150
- Werving
- Hamatologie-Onkologie im Zentrum MVZ GmbH /ID# 273043
-
Würzburg, Bavaria, Duitsland, 97080
- Werving
- Universitaetsklinikum Wuerzburg /ID# 275445
-
-
Hesse
-
Frankfurt am Main, Hesse, Duitsland, 60590
- Werving
- Universitaetsklinikum Frankfurt /ID# 268721
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Duitsland, 50937
- Werving
- Universitaetsklinikum Koeln /ID# 268489
-
Hemer, North Rhine-Westphalia, Duitsland, 58675
- Werving
- Lungenklinik Hemer /ID# 269779
-
-
Schleswig-Holstein
-
Oldenburg in Holstein, Schleswig-Holstein, Duitsland, 23758
- Werving
- ohO Research GmbH /ID# 273060
-
-
Thuringia
-
Jena, Thuringia, Duitsland, 07747
- Werving
- Universitatsklinikum Jena /ID# 269700
-
-
-
-
Gironde
-
Bordeaux, Gironde, Frankrijk, 33000
- Werving
- Institut Bergonie /ID# 258377
-
-
Loire-Atlantique
-
Saint-Herblain, Loire-Atlantique, Frankrijk, 44800
- Werving
- CHU Nantes - Hopital Laennec /ID# 268475
-
Saint-Herblain, Loire-Atlantique, Frankrijk, 44805
- Werving
- Institut de Cancerologie de l'Ouest Rene Gauducheau /ID# 268484
-
-
Occitanie
-
Montpellier, Occitanie, Frankrijk, 34070
- Werving
- Centre De Cancerologie Du Grand Montpellier /ID# 273724
-
-
Provence-Alpes-Côte d'Azur Region
-
Nice, Provence-Alpes-Côte d'Azur Region, Frankrijk, 06189
- Werving
- Centre Antoine-Lacassagne /ID# 268486
-
-
Val-de-Marne
-
Villejuif, Val-de-Marne, Frankrijk, 94805
- Werving
- Institut Gustave Roussy /ID# 258373
-
-
Île-de-France Region
-
Paris, Île-de-France Region, Frankrijk, 75248
- Werving
- Institut Curie /ID# 271395
-
-
-
-
-
Bologna, Italië, 40138
- Werving
- IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 268675
-
-
Forlì-Cesena
-
Meldola, Forlì-Cesena, Italië, 47014
- Werving
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST - IRCCS /ID# 268684
-
-
Milano
-
Milan, Milano, Italië, 20121
- Werving
- Istituto Europeo Di Oncologia /Id# 268670
-
-
Roma
-
Rome, Roma, Italië, 00144
- Werving
- IRCCS Istituti Fisioterapici Ospitalieri-Istituto Nazionale Tumori Regina Elena /ID# 268626
-
Rome, Roma, Italië, 00184
- Werving
- Azienda Ospedaliera Complesso Ospedaliero San Giovanni-Addolorata /ID# 273438
-
-
The Marches
-
Ancona, The Marches, Italië, 60126
- Werving
- Azienda Ospedaliero Universitaria delle Marche /ID# 268667
-
-
Torino
-
Orbassano, Torino, Italië, 10043
- Werving
- Azienda Ospedaliero Universitaria San Luigi Gonzaga /ID# 268641
-
-
-
-
-
Nagasaki, Japan, 852-8501
- Werving
- Nagasaki University Hospital /ID# 273310
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 460-0001
- Werving
- NHO Nagoya Medical Center /ID# 272515
-
Nagoya, Aichi-ken, Japan, 464-8681
- Werving
- Aichi Cancer Center /ID# 271978
-
-
Aomori
-
Hirosaki, Aomori, Japan, 036-8563
- Werving
- Hirosaki University Hospital /ID# 274410
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan, 221-0855
- Werving
- Yokohama Municipal Citizen's Hospital /ID# 271979
-
-
Kyoto
-
Kyoto, Kyoto, Japan, 606-8507
- Werving
- Kyoto University Hospital /ID# 272312
-
-
Niigata
-
Niigata, Niigata, Japan, 951-8520
- Werving
- Niigata University Medical and Dental Hospital /ID# 274448
-
-
Osaka
-
Takatsuki, Osaka, Japan, 569-8686
- Werving
- Osaka Medical And Pharmaceutical University Hospital /ID# 273309
-
-
Tokyo
-
Chuo-Ku, Tokyo, Japan, 104-0045
- Werving
- National Cancer Center Hospital /ID# 273192
-
Koto-ku, Tokyo, Japan, 135-8550
- Werving
- The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 271989
-
-
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Polen, 20-090
- Werving
- Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie /ID# 273170
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, Polen, 15-540
- Werving
- Uniwersytecki Szpital Kliniczny w Bialymstoku /ID# 276848
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, Polen, 80-214
- Werving
- Uniwersyteckie Centrum Kliniczne /ID# 272418
-
-
Świętokrzyskie Voivodeship
-
Kielce, Świętokrzyskie Voivodeship, Polen, 25-734
- Werving
- Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej /ID# 274549
-
-
-
-
-
Rio Piedras, Puerto Rico, 00935
- Werving
- Pan American Center for Oncology Trials - Rio Piedras /ID# 268827
-
-
-
-
-
Bucharest, Roemenië, 013975
- Werving
- MNT Healthcare Europe SRL /ID# 269075
-
Bucharest, Roemenië, 030171
- Werving
- Spitalul Clinic Coltea /ID# 268726
-
Sibiu, Roemenië, 550253
- Werving
- Clinica MedLife Polisano Sibiu /ID# 269078
-
-
Cluj
-
Cluj-Napoca, Cluj, Roemenië, 400080
- Werving
- S.C. Radiotherapy Center Cluj SRL /ID# 268729
-
Cluj-Napoca, Cluj, Roemenië, 400015
- Werving
- Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca /ID# 273125
-
Cluj-Napoca, Cluj, Roemenië, 400015
- Werving
- Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca /ID# 268725
-
-
-
-
-
A Coruña, Spanje, 15006
- Werving
- Complejo Hospitalario Universitario A Coruna /ID# 271456
-
Alicante, Spanje, 03010
- Werving
- Hospital General Universitario de Alicante /ID# 271316
-
Barcelona, Spanje, 08036
- Werving
- Hospital Clinic de Barcelona /ID# 271452
-
Barcelona, Spanje, 08041
- Werving
- Hospital Santa Creu i Sant Pau /ID# 271311
-
Barcelona, Spanje, 08003
- Werving
- Hospital del Mar /ID# 271310
-
Málaga, Spanje, 29010
- Werving
- Hospital Universitario Virgen de la Victoria /ID# 271312
-
-
Cantabria
-
Santander, Cantabria, Spanje, 39008
- Werving
- Hospital Universitario Marques de Valdecilla /ID# 271314
-
-
Sevilla
-
Seville, Sevilla, Spanje, 41009
- Werving
- Hospital Universitario Virgen Macarena /ID# 271447
-
-
-
-
-
Changhua, Taiwan, 500
- Werving
- Changhua Christian Hospital /ID# 280139
-
Chiayi City, Taiwan, 62247
- Werving
- Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation /ID# 268789
-
Kaohsiung City, Taiwan, 807
- Werving
- Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 268139
-
Kaohsiung City, Taiwan, 833
- Werving
- Kaohsiung Chang Gung Memorial Hospital /ID# 268138
-
Taipei, Taiwan, 114
- Werving
- Tri-Service General Hospital /ID# 269211
-
Taipei, Taiwan, 106
- Werving
- National Taiwan University Cancer Center (Ntucc) /ID# 271586
-
Taipei, Taiwan, 112
- Werving
- Taipei Veterans General Hospital /ID# 268787
-
Taoyuan City, Taiwan, 333
- Werving
- Linkou Chang Gung Memorial Hospital /ID# 268137
-
-
-
-
-
Adana, Turkije (Türkiye), 01140
- Werving
- Adana Medical Park Seyhan Hastanesi /ID# 272875
-
Ankara, Turkije (Türkiye), 06620
- Werving
- Ankara Universitesi Tip Fakultesi Cebeci Hastanesi /ID# 272873
-
Ankara, Turkije (Türkiye), 06680
- Werving
- Liv Hospital Ankara /ID# 272876
-
Ankara, Turkije (Türkiye), 06230
- Werving
- Hacettepe Universitesi Tip Fakultesi /ID# 280631
-
Denizli, Turkije (Türkiye), 20070
- Werving
- Pamukkale Universitesi /ID# 272893
-
Istanbul, Turkije (Türkiye), 34722
- Werving
- Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi /ID# 280635
-
Konya, Turkije (Türkiye), 42080
- Werving
- Necmettin Erbakan Universitesi Meram Tip Fakultesi - Eski Hastane /ID# 272882
-
Samsun, Turkije (Türkiye), 55139
- Werving
- Ondokuz Mayis Universitesi /ID# 272899
-
Samsun, Turkije (Türkiye), 55200
- Werving
- Samsun Medical Park Hastanesi /ID# 272880
-
-
Antalya
-
Ankara, Antalya, Turkije (Türkiye), 06010
- Werving
- Gulhane Egitim ve Arastirma Hastanesi /ID# 280715
-
-
Sakarya
-
Adapazarı, Sakarya, Turkije (Türkiye), 54290
- Werving
- Sakarya Egitim ve Arastirma Hastanesi /ID# 272878
-
-
-
-
-
Cardiff, Verenigd Koninkrijk, CF14 2TL
- Werving
- Velindre Cancer Centre /ID# 271840
-
-
Leicestershire
-
Leicester, Leicestershire, Verenigd Koninkrijk, LE1 5WW
- Werving
- University Hospitals of Leicester NHS Trust /ID# 276035
-
-
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85054
- Actief, niet wervend
- Mayo Clinic Hospital - Phoenix /ID# 272971
-
-
California
-
Fullerton, California, Verenigde Staten, 92835
- Werving
- Providence - St. Jude Medical Center /ID# 271414
-
Oxnard, California, Verenigde Staten, 93030
- Werving
- FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 274450
-
Santa Monica, California, Verenigde Staten, 90404
- Werving
- UCLA - Santa Monica /ID# 271690
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- Werving
- University Of Colorado - Anschutz Medical Campus /ID# 269069
-
Lone Tree, Colorado, Verenigde Staten, 80124
- Werving
- Rocky Mountain Cancer Centers - Lone Tree /ID# 272603
-
-
Florida
-
Jacksonville, Florida, Verenigde Staten, 32224
- Werving
- Mayo Clinic Hospital Jacksonville /ID# 275073
-
Orange City, Florida, Verenigde Staten, 32763
- Werving
- Mid Florida Hematology And Oncology Center /ID# 273777
-
-
Illinois
-
Hinsdale, Illinois, Verenigde Staten, 60521
- Werving
- Hope And Healing Cancer Services /ID# 276223
-
Contact:
- Site Coordinator
- Telefoonnummer: 6305600121
-
-
Indiana
-
Fort Wayne, Indiana, Verenigde Staten, 46845
- Werving
- Parkview Comprehensive Cancer Center /ID# 271879
-
Indianapolis, Indiana, Verenigde Staten, 46202
- Voltooid
- Community Health Network /ID# 273437
-
-
Kansas
-
Overland Park, Kansas, Verenigde Staten, 66210
- Werving
- Kansas City Cancer Center /ID# 273679
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02215
- Werving
- Dana-Farber Cancer Institute /ID# 278417
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48202
- Werving
- Henry Ford Hospital - Detroit /ID# 271642
-
-
Minnesota
-
Duluth, Minnesota, Verenigde Staten, 55805
- Werving
- St. Luke'S /ID# 273344
-
Rochester, Minnesota, Verenigde Staten, 55905
- Werving
- Mayo Clinic-Rochester /ID# 274512
-
-
New Jersey
-
East Brunswick, New Jersey, Verenigde Staten, 08816-4096
- Werving
- Astera Cancer Care /ID# 271915
-
-
New York
-
Shirley, New York, Verenigde Staten, 11967
- Werving
- New York Cancer And Blood Specialists - Shirley /ID# 272547
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten, 44106
- Voltooid
- University Hospitals Cleveland Medical Center /ID# 271726
-
Columbus, Ohio, Verenigde Staten, 43219
- Werving
- The Mark H Zangmeister Center /ID# 272502
-
-
Pennsylvania
-
Easton, Pennsylvania, Verenigde Staten, 18045
- Werving
- Spoknwrd Clinical Trials /ID# 273776
-
Contact:
- Site Coordinator
- Telefoonnummer: 610-813-2087
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77090
- Voltooid
- Millennium Physicians /ID# 271717
-
Lubbock, Texas, Verenigde Staten, 79410-1121
- Werving
- Joe Arrington Cancer Research /ID# 272776
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84112
- Werving
- Huntsman Cancer Institute /ID# 271686
-
-
Virginia
-
Leesburg, Virginia, Verenigde Staten, 20176
- Werving
- Virgnia Cancer Specialists /ID# 269633
-
-
Washington
-
Olympia, Washington, Verenigde Staten, 98506
- Werving
- Vista Oncology - East Olympia /ID# 275438
-
Tacoma, Washington, Verenigde Staten, 98405
- Werving
- Northwest Medical Specialties Tacoma /ID# 270469
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Must have histologically documented non-squamous (NSq) non small cell lung carcinoma (NSCLC) that is locally advanced or metastatic will be enrolled into the study.
- Must have measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.
- For Part 1, participants must have had no more than 1 systemic therapy for advanced disease including platinum-based chemotherapy or an immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy), or appropriate targeted therapy for an actionable gene alteration, if applicable, for epidermal growth factor receptor (EGFR) wild-type (WT) NSq NSCLC.
- For Part 2, participants must have no prior systemic therapy for advanced disease, no known actionable genomic alteration.
- Must have documented programmed death ligand 1 (PD-L1) status.
- For Part 2, participant must have evaluable c-Met immunohistochemistry (IHC) result per central testing prior to randomization.
- Must have adequate organ function.
Exclusion Criteria:
- Known uncontrolled metastases to the central nervous system.
- History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis on screening chest computed tomography (CT) scan.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Part 1: Telisotuzumab Adizutecan + Budigalimab
Participants will receive several doses of telisotuzumab adizutecan in combination with budigalimab, as part of the 33 month study duration. |
Intravenous (IV) Infusion
Andere namen:
IV Infusion
Andere namen:
|
|
Experimenteel: Part 2 Arm 1: Telisotuzumab Adizutecan + Pembrolizumab
Participants will receive telisotuzumab adizutecan dose A in combination with pembrolizumab, as part of the 33 month study duration. |
Intravenous (IV) Infusion
Andere namen:
IV Injection IV Infusion |
|
Experimenteel: Part 2 Arm 2: Telisotuzumab Adizutecan + Pembrolizumab
Participants will receive telisotuzumab adizutecan dose B in combination with pembrolizumab, as part of the 33 month study duration. |
Intravenous (IV) Infusion
Andere namen:
IV Injection IV Infusion |
|
Experimenteel: Part 2: Standard of Care
Participants will receive pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed, as part of the 33 month study duration. |
IV Infusion IV Infusion IV Injection IV Infusion IV Infusion |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Part 1: Dose-Limiting Toxicities (DLT)s of Telisotuzumab Adizutecan
Tijdsspanne: Up to Approximately 84 Days
|
DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications. |
Up to Approximately 84 Days
|
|
Part 2: Objective Response (OR) as Assessed by Blinded Independent Central Review (BICR)
Tijdsspanne: Up to Approximately 33 Months
|
OR is defined as confirmed complete response (CR) or confirmed partial response (PR) per BICR based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. |
Up to Approximately 33 Months
|
|
Number of Participants with Adverse Events (AE)s
Tijdsspanne: Up to Approximately 33 Months
|
An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. |
Up to Approximately 33 Months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Part 1 and Part 2: PFS as Assessed by Investigator
Tijdsspanne: Up to Approximately 33 Months
|
PFS is defined as the time from the participant's randomization date to the first occurrence of radiographic progression per Investigator based on RECIST v1.1 or death from any cause, whichever occurs earlier. |
Up to Approximately 33 Months
|
|
Part 1 and Part 2: DOR as Assessed by Investigator
Tijdsspanne: Up to Approximately 33 Months
|
DOR is defined as the time from the first documented CR or PR per investigator to the first occurrence of radiographic progression per the investigator on RECIST v1.1 or death from any cause, whichever occurs first. DOR is defined for participants with confirmed CR/PR. |
Up to Approximately 33 Months
|
|
Part 1 and Part 2: DC as Assessed by Investigator
Tijdsspanne: Up to Approximately 33 Months
|
DC is defined as best overall response of confirmed CR or confirmed PR, or SD for at least 11 weeks following randomization date based on RECIST v1.1, as determined by the Investigator. |
Up to Approximately 33 Months
|
|
Part 1 and Part 2: Overall Survival (OS)
Tijdsspanne: Up to Approximately 33 Months
|
OS is defined as the time from participant's randomization date (Part 2) or first dose date of study treatment (Part 1) to the event of death from any cause. |
Up to Approximately 33 Months
|
|
Programmed Death Ligand 1 (PD-L1) and c-Met Subgroups: OR
Tijdsspanne: Up to Approximately 33 Months
|
OR is defined as confirmed CR or confirmed PR based on RECIST v1.1. |
Up to Approximately 33 Months
|
|
PD-L1 and c-Met Subgroups: PFS
Tijdsspanne: Up to Approximately 33 Months
|
PFS is defined as the time from the participant's randomization date to the first occurrence of radiographic progression based on RECIST v1.1 or death from any cause, whichever occurs earlier. |
Up to Approximately 33 Months
|
|
PD-L1 and c-Met Subgroups: OS
Tijdsspanne: Up to Approximately 33 Months
|
OS is defined as the time from participant's randomization date (Part 2) or first dose date of study treatment (Part 1) to the event of death from any cause. |
Up to Approximately 33 Months
|
|
PD-L1 and c-Met Subgroups: DOR
Tijdsspanne: Up to Approximately 33 Months
|
DOR is defined as the time from the first documented CR or PR to the first occurrence of radiographic progression per RECIST v1.1 or death from any cause, whichever occurs first. DOR is defined for participants with confirmed CR/PR. |
Up to Approximately 33 Months
|
|
PD-L1 and c-Met Subgroups: DC
Tijdsspanne: Up to Approximately 33 Months
|
DC is defined as best overall response of confirmed CR or confirmed PR, or SD for at least 12 weeks following randomization date based on RECIST v1.1. |
Up to Approximately 33 Months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: ABBVIE INC., AbbVie
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Ziekten van de luchtwegen
- Longziekten
- Neoplasmata van de luchtwegen
- Thoracale neoplasmata
- Longneoplasmata
- Carcinoom, bronchogeen
- Bronchiale neoplasmata
- Carcinoom, niet-kleincellige long
- Aminozuren, peptiden en eiwitten
- Organische chemicaliën
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Anorganische chemicaliën
- Chloorverbindingen
- Stikstofverbindingen
- Coördinatiecomplexen
- Guanine
- Hypoxanthines
- Purinones
- Purines
- Glutamaten
- Aminozuren, zuur
- Aminozuren
- Aminozuren, dicarbonylisch
- Platinumverbindingen
- Pemetrexed
- Carboplatine
- Cisplatine
- pembrolizumab
- Budigalimab
Andere studie-ID-nummers
- M24-536
- 2024-514465-18 (Andere identificatie: EU CT)
- 2024-514465-18-00 (Ctis)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD-tijdsbestek voor delen
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
IPD-toegangscriteria voor delen
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .